Beam Therapeutics Inc. Common Stock

BEAMNASDAQ • USD
ThemeGenomics & Precision Med.›Gene Therapy & Gene Editing
25.23 USD
↘ 0.44 (1.71%)AT CLOSE (03:59 PM EDT)
25.45
↗ 0.22 (0.87%)
POST MARKET (AS OF 05:05 PM EDT)
Post Market
AS OF 05:05 PM EDT
25.45
↗ 0.22 (0.87%)
🟢Market: OPEN

BEAM is currently priced at $25.45. Both sides of the analysis point lower: technicals flash "Sell" and fundamentals confirm with a "Sell" reading. This is driven by a robust Altman Z-Score, a weak Piotroski F-Score of 1/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. On valuation, BEAM trades roughly in line with sector averages — neither particularly cheap nor expensive.

Technical & fundamental data as of Oct 6, 2026.

Open?$26.80
High?$26.94
Low?$24.87
Prev. Close?$25.67
Volume?2.5M
Avg. Volume?1.8M
VWAP?$25.56
Rel. Volume?1.37x
Bid / Ask
Bid?$21.46 × 100
Ask?$28.66 × 100
Spread?$7.20
Midpoint?$25.06
Valuation & Ratios
Market Cap?2.7B
Shares Out?103.3M
Float?82.0M
Float %?79.4%
P/E Ratio?N/A
P/B Ratio?2.48
EPS?-$0.83
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
Themes
Healthcare - Genomics & Precision Medicine›Gene Therapy & Gene EditingBiotech - Drug Development›Rare Disease Therapeutics
Employees
540
Market Cap
2.7B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.beamtx.com
Listed
2020-02-06
Address
26 LANDSDOWNE STREET
CAMBRIDGE, MA 02139
Phone: 857-327-8775
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▲ Bullish(+1/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
6
Z-Score?
79
Momentum?
23
Short Sent.?
10
Piotroski F-Score?1/9Weak
Altman Z-Score?3.27Safe
Confidence?58%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?31.57%Squeeze Risk
Short Interest?25.9M
Days to Cover?12.6
Free Float82.0M
Avg Daily Volume2.1M
Settlement Date2026-09-15
Financial Health
Current Ratio?14.57Strong
Quick Ratio?14.57Strong
Cash Ratio?2.72Strong
Debt/Equity?0.09Low
ValuationFAIRLY VALUEDvs 5 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
Peers
83
S&P
65
2.48CHEAP▾
P/S?
Peers
83
S&P
3
16.99HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-7.1CHEAP▾
EV/Sales?
Peers
83
S&P
3
16.23HIGH▾
Returns & Efficiency
ROE?
S&P
10
-8.0%WEAK▾
ROA?
S&P
3
-6.2%WEAK▾
Cash Flow & Enterprise
FCF?$-372768000
Enterprise Value?$2.5B
Fundamentals ratios updated end of day
MarketsMoversWatchlist